Transmedics Group Stock

Transmedics Group EBIT

The EBIT of Transmedics Group (TMDX) as of Aug 4, 2026 is 108.58 M USD. In the previous year, EBIT was 37.50 M USD — a change of 189.59% (higher).

EBIT

108.58 MUSD

YoY

189.59%

Last updated:

In 2026, Transmedics Group's EBIT was 108.58 M USD, a 189.59% increase from the 37.50 M USD EBIT recorded in the previous year.

The Transmedics Group EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2022
-32.44 base
Jan 1, 2023
-28.73 base
Jan 1, 2024
37.50 base
Jan 1, 2025
108.58 base
Jan 1, 2026 (e)
-160.93 base
Jan 1, 2027 (e)
-190.72 base
Jan 1, 2028 (e)
-221.45 base
Jan 1, 2029 (e)
-258.09 base
YEAREBIT (M USD)
2029 est -258.09
2028 est -221.45
2027 est -190.72
2026 est -160.93
2025 108.58
2024 37.50
2023 -28.73
2022 -32.44
2021 -40.31
2020 -24.73
2019 -29.15
2018 -21.00
2017 -19.72
2016 -23.09
2006 -18.24
Access this data via the Eulerpool API

Transmedics Group Revenue

Transmedics Group Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
93.46 M USD
-32.44 M USD
-36.23 M USD
Jan 1, 2023
241.62 M USD
-28.73 M USD
-25.03 M USD
Jan 1, 2024
441.54 M USD
37.50 M USD
35.46 M USD
Jan 1, 2025
605.49 M USD
108.58 M USD
190.29 M USD
Jan 1, 2026 (e)
732.29 M USD
-160.93 M USD
60.98 M USD
Jan 1, 2027 (e)
867.85 M USD
-190.72 M USD
105.31 M USD
Jan 1, 2028 (e)
1.01 B USD
-221.45 M USD
154.96 M USD
Jan 1, 2029 (e)
1.17 B USD
-258.09 M USD
186.23 M USD

Transmedics Group Margins

Transmedics Group stock margins

The Transmedics Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Transmedics Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Transmedics Group.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
69.84 %
-34.71 %
-38.77 %
Jan 1, 2023
63.77 %
-11.89 %
-10.36 %
Jan 1, 2024
59.36 %
8.49 %
8.03 %
Jan 1, 2025
59.92 %
17.93 %
31.43 %
Jan 1, 2026 (e)
59.92 %
-21.98 %
8.33 %
Jan 1, 2027 (e)
59.92 %
-21.98 %
12.13 %
Jan 1, 2028 (e)
59.92 %
-21.98 %
15.38 %
Jan 1, 2029 (e)
59.92 %
-21.98 %
15.86 %

Transmedics Group Stock analysis

What does Transmedics Group do? Transmedics Group Inc is a company dedicated to the development and manufacturing of medical devices for organ transplantation. The company was founded in 1998 and is headquartered in Andover, Massachusetts, USA. Transmedics' business model is based on offering a unique and innovative technology for organ preservation during transport from donor to recipient. The patented Organ Care System (OCS) platform includes a range of state-of-the-art medical devices specifically designed for organ transport. Transmedics' Organ Care System includes three main devices: OCS Heart, OCS Lung, and OCS Liver. Each device is tailored for organ preparation and transport, providing individualized support based on the specific requirements of each organ and different transfer protocols. The OCS technology uses hypothermic (cold) perfusion to preserve the organ during transport. By continuously monitoring and supporting the organ's physiological functions, the OCS system can improve the survival rate of donor organs while reducing the time spent outside the body. Transmedics also offers comprehensive services, including the availability of OCS devices and qualified personnel to provide support throughout the transplantation process. Transmedics' customers include leading transplant centers and hospitals worldwide. The company works closely with these customers to ensure that its OCS devices meet the specific requirements of each transplantation program and help them achieve more successful transplantations. Transmedics' history is marked by a passion for improving transplantation medicine and saving lives through the provision of advanced technologies and solutions. The company has made significant progress in recent years and has experienced strong growth in all areas. Transmedics has also received a number of awards and recognition for its commitment to improving transplantation medicine. For example, in 2020, the company received the Red Herring Top 100 Global Award and was recognized for the seventh consecutive year as one of the fastest-growing companies by Deloitte. Overall, Transmedics is a leading provider of innovative medical devices for transplantation medicine. Through its organic technology and comprehensive service, the company supports transplant centers and hospitals worldwide in performing more successful transplantations and saving patients' lives. Transmedics Group is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Transmedics Group's EBIT

Transmedics Group's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Transmedics Group's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Transmedics Group's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Transmedics Group’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Transmedics Group stock

EBIT of Transmedics Group is 108.58 M USD in 2026.

EBIT of Transmedics Group changed from 37.50 M USD to 108.58 M USD, representing a 189.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Transmedics Group since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Transmedics Group historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Transmedics Group

All Key Metrics — Transmedics Group